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Abstract
Despite antiretroviral therapy, proviral latency of human immunodeficiency virus type 1 (HIV-1) 
remains a principal obstacle to curing the infection [1]. Inducing the expression of latent genomes 
within resting CD4+ T cells is the primary strategy to clear this reservoir [2]. While histone 
deacetylase (HDAC) inhibitors such as suberoylanilide hydroxamic acid (SAHA or vorinostat, 
VOR) can disrupt HIV-1 latency in vitro [3–5], the utility of this approach has never been directly 
proven in a translational clinical study of HIV-infected patients.
Therefore we isolated the circulating resting CD4+ T cells of patients in whom viremia was fully 
suppressed by antiretroviral therapy (ART), and directly studied the effect of VOR in this latent 
reservoir. In each of eight patients studied, a single dose of VOR increased both biomarkers of 
cellular acetylation, and simultaneously induced an increase in HIV RNA expression in resting 
CD4+ cells (mean increase 4.8-fold). This is the first demonstration that a molecular mechanism 
known to enforce HIV latency can be therapeutically targeted in man, provides proof-of-concept 
for HDAC inhibitors as a new therapeutic class, and defines a precise approach to test novel 
strategies to directly attack and eradicate latent HIV infection.
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Among the many important aims of future HIV research is the development of therapies of 
finite duration capable of eradicating HIV infection. The persistence of quiescent HIV 
infection within a small population long-lived CD4+ T cells is currently a major obstacle to 
this goal [1]. HDACs are recruited to the HIV long terminal repeat promoter (LTR), 
establishing one of several restrictions that can limit LTR expression and maintain viral 
latency [2]. Deacetylated LTR chromatin appears to play a key contributory role in 
regulating HIV expression, and especially in maintaining proviral quiescence and latency. In 
vitro, HDAC inhibitors have been shown to disrupt latent proviral HIV infection in both cell 
culture models and ex vivo assays using cells from HIV-1-infected patients. While 
disrupting latency has been proposed as part of a strategy to eradicate HIV infection, 
previous studies using the weak HDAC inhibitor valproic acid did not consistently 
demonstrate a marked depletion of resting cell infection [6–10] in patients on ART. 
However, the effects measured in these studies are significantly downstream of the 
molecular site of action HDAC inhibitors, and thus the proximal pharmacodynamic 
measures of HDAC inhibitor activity and HIV-1 expression were not evaluated. Here we 
show that HDAC inhibitors disrupt the latency of proviral genomes within resting CD4+ T 
cells, establishing the first class of drugs that could lead to the eradication of HIV infection.
Suberoylanilide hydroxamic acid (vorinostat, VOR) is a potent HDAC inhibitor used to treat 
human malignancies. At clinically relevant concentrations VOR inhibits the Class I HDACs 
most important for repression of HIV expression [3, 11], and induces LTR expression and 
virus production in vitro from the resting CD4+ T cells of HIV+ patients on ART with levels 
of plasma HIV RNA below the limit of detection (BDL) [4–5,12]. As the most proximal 
measure of effect on latent infection is expression of HIV-1 RNA, we developed a sensitive 
assay to enable a direct measurement of unspliced gag HIV RNA within the resting CD4+ T 
cells of HIV-infected patients. The assay has a limit of detection of 1 copy/million resting 
CD4+ T cells, and a limit of quantitation of 10 copies/million resting CD4+ T cells.
To evaluate the effect of VOR on latent infection in vivo, HIV-infected patients receiving 
stable ART with plasma HIV-1 RNA < 50 copies/ml for at least 6 months and a CD4 count 
>300/µl were enrolled following informed consent. First, to demonstrate that it was ethical 
to expose patients to an experimental agent with potential risk in a study with no proven 
clinical benefit for the individual, we validated the ability of this assay of HIV RNA within 
resting CD4+ T cells to measure HIV expression at baseline, and to detect up-regulation of 
HIV expression in resting cells from each patient after physiological exposure to VOR.
Patients maintained suppressive ART, and purified populations of resting CD4+ T cells were 
obtained by continuous-flow leukopheresis and negative selection in an immunomagnetic 
column [7]. To establish a baseline, we measured the mean quantity of HIV-1 gag RNA in 
pools of 1 million resting CD4+ T cells immediately after their isolation from patients. To 
measure validated biomarkers of VOR effect in the PBMCs of patients, we performed 
parallel assays of total cellular histone acetylation and measured histone acetylation by 
chromatin immunoprecipitation (ChIP) at the human p21 gene promoter, a gene known to 
upregulate chromatin acetylation after VOR exposure [13]. Then to model the effect of a 
clinical dose of VOR, multiple replicate pools of 1 million resting CD4+ T cells were 
incubated in complete media alone, with 335 nM VOR, or with 3 µg PHA and 60 U IL-2 for 
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6 hours. VOR conditions were selected to mimic the unbound drug exposure expected after 
a single 400 mg dose of VOR in vivo [4].
Validation assays were performed in resting CD4+ T cells isolated by leukapheresis from 16 
patients with plasma HIV RNA BDL (Fig. 1A). In each patient a total of 48–72 million 
highly purified resting CD4+ T cells were studied; 12–48 million cells in each condition, 
depending on cell availability. In 9 patients baseline expression following 6 hours of culture 
of 16–24 million cells without stimulation in media alone, HIV gag RNA was quantifiable at 
a mean level of 52 +/− 32 copies/million cells. However, in the other 7 patients in whom 
12–24 million cells were studied (Fig. 1A), HIV RNA was not quantifiable at a limit of 10 
copies/million cells, although in all but 2 of these patients RNA was detected but not 
quantifiable (>0 but <10 copies/million cells).
Following in vitro exposure to 335 nM VOR for 6 hours, HIV RNA expression was 
significantly upregulated in 8 of 9 patients in whom resting CD4+ T cell HIV RNA was 
quantifiable without HDAC inhibitor exposure, and also in 3 of 7 patients in whom cell-
associated HIV RNA was < 10 copies before HDAC inhibitor exposure. In all 11 patients in 
whom expression was induced by VOR, HIV RNA expression was also induced after 6 
hours of exposure to PHA. Levels of HIV RNA induction were similar after 6 hours of 
exposure to PHA or VOR, although in other experiments (data not shown) levels of HIV 
RNA plateaued after 6 hours of exposure to VOR, but continued to increase when PHA 
exposure was extended for up to 16 hrs.
Of the 11 eligible patients in whom an induction of HIV RNA expression following in vitro 
exposure to VOR could be measured, eight patients (Fig. 1B; CD4 count 432–1147/µl, mean 
713/µl) continued their long-term ART (tenofovir, emtricitabine, and efavirenz in all) and 
agreed to receive a single dose of VOR at 200 mg to ascertain tolerability. Global cellular 
histone acetylation in PBMCs was unchanged up to 24 hours after dosing, and histone 
acetylation at the human p21 gene promoter was modestly increased in only two patients 
(data not shown).
Two to four weeks later the safety and tolerability of a 400 mg dose of VOR was assessed, 
including acetylation measurements, and VOR plasma concentrations measured serially up 
to 24 hours after dosing (Fig. 2). Maximum VOR concentrations of 244 ng/ml (median, 
range 153–301) occurred a median of two hours (range 0.5–4) after dosing. VOR 
pharmacokinetics were similar to those reported in other populations [14, 15]. This exposure 
resulted in a significant increase (p < 0.01) in acetylation of total cellular histone H3 
(median 1.6-fold) in all eight patients, and trend towards increased acetylation of histones at 
the human p21 gene as measured by chromatin immunoprecipitation in patients 2–5, and 7 
for whom sufficient cells were available (Fig. 2).
Four to five weeks later a second dose of 400 mg of VOR was administered and resting 
CD4+ T cells collected 4–7 hours later, after the previously measured peak VOR level. We 
measured HIV RNA in multiple pools of resting CD4+ T cells within this window of time, 
when cellular biomarkers of increased acetylation had been previously documented, and 
induction of HIV LTR expression mediated by HDAC inhibitor activity would be possible. 
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During exposure to VOR, an increase of 1.5- to 10.0-fold (mean 4.8) in expression of 
unspliced HIV-1 gag RNA within resting CD4+ T cells was measured in all seven patients 
(Fig. 3). Expression following the 400 mg dose was significantly increased (p<0.01) when 
compared to baseline levels of RNA expression for all patients. Patients 1 and 2 underwent 
leukapheresis 3 to 4 months after dosing and protocol completion to provide cells for other 
research, and in both cases a statistically significant decline in HIV RNA expression per 
million resting CD4+ T cells after VOR dosing was observed (patient 1: after VOR 290 
copies, off-protocol 70 copies/106 cells, p < 0.001; patient 2: after VOR 186 copies, off-
protocol 105 copies/106 cells, p = 0.003). These observations support the conclusion that the 
increase in HIV RNA expression was causally related to VOR exposure. This conclusion 
assumes that the isolation of RNA from resting CD4+ T cells largely excludes actively 
infected cells, and reflects RNA expression in cells that are functionally defined as latently 
infected [16].
Throughout this limited exposure, VOR was well tolerated with no adverse events greater 
than Grade I, none of which were attributable to VOR. Additionally, we measured single-
copy assay viremia [17] on four occasions prior to VOR exposure, and at 8 and 24 hours 
after doses of 200, 400, and 400 mg of VOR (10 assays in total). Despite the upregulation of 
HIV RNA expression measured in circulating resting CD4+ T cells, no significant change of 
low-level viremia was observed. Median plasma HIV RNA/ml by single-copy assay was 13 
(range 3 to 23), < 1.0 (range <1 to 3), 2 (range < 1 to 3), < 1 (range <1 to 1), 3 (range 1 to 6), 
< 1 (range <1 to 5), <1 (range <1 to 1.2), and <1 in all assays, with no consistent trend 
towards an increase in plasma HIV RNA after VOR exposure.
This study is the first clear demonstration that the quiescence of latent, integrated HIV 
provirus within resting CD4+ T cells, a significant barrier to the eradication of HIV 
infection, can be disrupted by an achievable and tolerable exposure to an HDAC inhibitor. A 
single, clinically tolerable dose of VOR induces the expected biological effect --- histone 
acetylation --- consistent with HDAC inhibitor exposure within the PBMCs of HIV-infected, 
ART-treated patients. These effects are temporally associated with increased levels of HIV 
RNA expression detected within resting CD4+ T cells, demonstrating that, at least for a 
period of time in some infected cells, all of the restrictions that limit the expression of latent 
proviral genomes have been overcome. Nevertheless, while histone deacetylation is 
associated with HIV RNA expression, the precise molecular mechanisms through which 
VOR mediates this effect remain to be fully explained.
HIV RNA induction in vivo often appeared to be of greater magnitude than that seen in 
vitro, perhaps due to an underestimation in the modeling of physiological exposure in vitro, 
or other phenomenon induced by drug exposure in vivo. Further testing will be required to 
determine if the in vitro assay presented herein is predictive of a subset of patients who do 
not respond to VOR, or if such pre-screening is unnecessary. Nevertheless, assays of HIV 
RNA associated with resting CD4+ T cells may be useful in the pre-clinical and clinical 
testing of new and combination approaches to disrupt HIV latency.
Precise studies will be required to determine which dosing regimens of VOR or other 
HDAC inhibitors are safe and result in sustained disruption of HIV latency. We did not 
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observe an alteration of low-level viremia, perhaps due to the very low levels of plasma 
viremia present in these patients at baseline, that our sampling did not capture the brief 
effect of a single exposure to VOR, or that stable, low-level viremia reflects virion 
production from sources other than resting CD4+ T cells. Further, a limited evaluation did 
not reveal a substantial reduction in the frequency of replication-competent HIV within 
resting CD4+ T cells (data not shown). This is not surprising as such an effect is likely to 
require more than a single dose of VOR, or additional interventions to clear infected cells. 
These are important goals for future studies.
VOR, like the HDAC inhibitor in wide clinical use, valproic acid, is deemed a mutagen as 
predicted by the Ames test in bacteria, although DNA damage induced by VOR is known to 
be repaired in normal human cells [18, 19]. Mutations in normal cells are not observed 
following long-term growth in the presence of VOR [20]. Nevertheless, the risks and 
benefits of attempts to eradicate HIV infection will have to be carefully weighed. While it 
remains to be seen if the use of VOR in combination with suppressive ART is sufficient to 
result in the depletion of latently infected resting CD4+ T cells, or whether additional 
interventions are required, these findings demonstrate that therapy targeted at persistent, 
latent infection within resting CD4+ T cells is feasible, and open the way for the 
development of HDAC inhibitors with improved specificity, potency, and safety profiles for 
the selective targeting of latent proviral genomes.
Methods
Patients/Study Procedures
HIV-infected patients receiving stable, standard-of-care ART with plasma HIV-1 RNA < 50 
copies/ml and a CD4 count of >300/µl for at least 6 months were enrolled following 
informed consent. Studies were approved by the UNC institutional biomedical review board 
and the Food and Drug Administration. Leukapheresis was performed and ex vivo VOR 
response assayed. Patients with ex vivo VOR response were then administered a 200 mg 
dose of VOR (donated by Merck Research Laboratories, West Point, PA) to assess safety 
and tolerability, followed by a 400 mg dose 4 or more weeks later during which 
pharmacokinetic parameters, including maximum concentration (Cmax) peak and apparent 
oral clearance (CL/F), as well as levels of global cellular histone and human p21 promoter 
histone H3 acetylation. A second 400 mg dose of VOR was administered 4 or more weeks 
later, and apheresis spanning the time point of measured Cmax VOR concentrations was 
performed to assay in vivo VOR response.
Measurement of Resting CD4+ T cell-associated HIV-1 RNA
Leukapheresis and isolation of resting CD4+ T cells have been described elsewhere [4]. To 
measure the ex vivo response of resting CD4+ T cells to VOR, cells were incubated in media 
containing 335 nM VOR (Merck Research Laboratories) or 3 µg/ml PHA (Remel, Lenexa, 
KS) and 60 U/ml IL-2 or media alone for 6 hrs. Cells were washed and plated at 1 million/ 
well in a 96-well plate and pelleted. Cell pellets were snap frozen and stored at −80°C. To 
measure the in vivo response to VOR, immediately following leukapheresis, resting CD4+ 
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T-cells were isolated and plated at 1 million cells/ well, pelleted, snap frozen, and stored at 
−80°C.
Total RNA was isolated from 12 to 48 pools of 1 million resting cells using the Magmax 96 
Total RNA isolation kit (Ambion, Austin, TX) following the manufacturer’s protocol. 
Duplicate pools of cDNA were synthesized from DNase-treated, isolated RNA using the 
SuperScript® III First-Strand Synthesis SuperMix kit (Invitrogen, Carlsbad, CA) according 
to the manufacturer’s procedures. Two additional duplicates wells from each treatment 
condition did not include reverse transcriptase and served as control for DNA 
contamination. Duplicate PCR amplification of duplicate cDNA was performed using the 
ABI7500 Fast Real-Time PCR machine and previously published primers and probe [20]. A 
standard curve was generated for each PCR reaction using cDNA synthesized from in-vitro 
transcribed RNA where the p5’ plasmid served as template [22]. Results of the four PCR 
replicates representing each of the original 12 to 48 pools of RNA were averaged and the 
standard deviation determined for each condition. Inputs for samples in which basal and 
VOR-induced HIV RNA expression were measured (Fig. 3) were compared by the 
quantitation of TATA Binding Protein RNA [23] and the quantitation of total HIV DNA, 
and showed no trend towards higher values in the post-VOR samples.
We determined that our HIV RNA PCR assay could detect the difference between 1 copy 
and ≥10 copies using dilutions of an HIV RNA internal standard [24]. Detectable PCR 
signal less than 10 copies (1–9 copies) was treated in all analyses as 5 copies. No PCR 
signal or < 1 copy was treated in all analyses as 0 copies. As the entire pool of cDNA was 
not amplified, and individual PCR amplifications are therefore subject to stochastic 
sampling effects, we have termed the result “relative HIV-1 gag RNA copies.” The 
Wilcoxon rank sum test was used to calculate the statistical significance of all comparisons 
between conditions.
Measurement of total histone acetylation by flow cytometry
PBMCs collected before and after 400 mg VOR dosing were fixed and permeabilized using 
Phosflow fix buffer I and Phosphflow permeabilization buffer II (BD Biosciences, San 
Diego, CA) according to the manufacturer’s protocol. Cells were then washed in stain buffer 
(2% FBS, 0.09 % sodium azide), blocked with 8% normal goat serum (Invitrogen), and 
incubated with anti-acetyl histone H3 (1:100 dilution, catalog #06-599, Millipore, Billerica, 
MA) or control rabbit IgG, in blocking solution for 60 minutes at room temperature. Cells 
were then washed and incubated with goat-anti-Rabbit IgG FITC conjugated secondary 
antibody (1: 250 dilution, Millipore, Billerica, MA) in stain buffer for 30 min at 25°C in the 
dark. Following a final wash, cells were analyzed by flow cytometry using a CyAn ADP 
flow cytometer and Summit 4.3 software (Beckman Coulter Inc, Miami, FL).
Chromatin Immunoprecipitation (ChIP)
ChIP assays were performed as previously described [8] with the following modifications: 
PBMCs were crossed-linked with 1% Formaldehyde and nuclei extracted using the 
appropriate buffers (Diagenode, Denville, NJ). Nuclei were lysed using an SDS lysis buffer 
containing mammalian protease cocktail inhibitor (Sigma, St Louis, MO) and sonicated to 
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fragment chromatin to 500–1000 base pairs using a Bioruptor standard sonicator 
(Diagenode, Denville, NJ). 1 × 106 sonicated cells were used to set up each 
immunoprecipitation reaction using 5 µg of anti-acetyl-histone H3 (Ac-H3 catalogue #17–
615, Millipore) or rabbit pre-immune immunoglobulin G (Sigma). PCR of 
immunoprecipitates or input DNA was performed using primers targeting the human p21 
promoter [25]. The percent of immunoprecipitated p21 promoter DNA was determined by 
comparing the cycle threshold values of each reaction to a standard curve generated from 
input DNA and is reported as the percent of input.
Measurement of Vorinostat PK
Five milliliters of blood was collected without anticoagulant for pharmacokinetic assays 
before dose and at 0.25, 0.50, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, and 24 hours after dosing. 
Blood samples were allowed to clot at room temperature for 30 minutes, centrifuged at 
2,000× g for 15 minutes at 4°C, and stored at −70°C until analysis. Vorinostat 
concentrations were measured from human serum using a modification of the method by Du 
et al. [14]. Individual serum concentrations were used to estimate vorinostat 
pharmacokinetic variables AUC0–24h, Cmax, Tmax, CL/F, and apparent terminal t1/2. 
WinNonlin Phoenix was used for the calculations. The apparent terminal t1/2 was estimated 
from the best-fit variables of a single exponential to the log-linear portion of the serum 
concentration/time curve using unweighted linear regression. AUC0–24h was calculated 
using the linear up/log down method. Cmax and Tmax were obtained by inspection of the 
concentration-time data.
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Figure 1. The relative HIV-1 RNA copy number in resting CD4+ T cells of 13 ART-treated HIV+ 
patients with plasma HIV RNA BDL
Values are calculated by cycle number, and limit of quantitation of cell-associated RNA is 
10 copies. Cells were cultured alone (untreated), with VOR 335 nM (VOR), or activated 
with 3 µg/ml PHA and 60 U/ml IL2 for 6 hours. Data from 16 patients (a), and those who 
later received in vivo dosing [1 (Δ), 2 (□), 3 (◊), 4 (X), 5 (▽), 6 (❍), 7 (+), and 8 (⨀)] are 
shown in detail (b, mean and s.d.).
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Figure 2. VOR exposure and histone acetylation
Median VOR plasma concentrations in patients 1–8 after a single 400 mg oral dose (circles 
with range shown) is shown in comparison to mean total cellular acetylated histone H3 in 
PBMCs (diamonds with s.d. shown), and relative levels of acetylated histone H3 at the 
human p21 gene promoter in resting CD4+ T cells (bars, mean and s.d.). A significant 
increase (†) in cellular acetylated histone H3 is seen at 8 hours, p < 0.01. A trend towards 
increased acetylation at the p21 gene is seen in the patients (2–5, 7) in whom sufficient cells 
were available for analysis.
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Figure 3. VOR upregulates HIV RNA expression
The relative HIV-1 RNA copy number (mean, s.d.) measured in the resting CD4+ T cells of 
eight HIV+ patients with plasma HIV RNA BDL is shown on background ART and on ART 
following a single 400 mg oral dose of VOR. For each subject, the differences are 
significant (p < 0.01).
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